Compounded Tirzepatide: How It Works, Side Effects, and Who It's Not For

Compounded tirzepatide and the manufacturer's tirzepatide are not interchangeable, and the difference shapes how you should read the research. Start with what the molecule does.

What is tirzepatide?

Tirzepatide is a prescription peptide that acts on two hormone receptors involved in appetite and blood sugar: GIP and GLP-1. Both are hormones your gut releases after you eat. A 2018 paper in Molecular Metabolism (Coskun et al.) describes how the molecule was designed to activate both receptors, and its early testing in animals and people.

In plain terms, tirzepatide:

• Signals fullness to the brain, which may reduce appetite
• Slows how fast food leaves the stomach
• Helps the pancreas release insulin when blood sugar is high

Physicians use tirzepatide for weight management, together with nutrition and physical activity.

What "compounded" means

Compounded tirzepatide is prepared by a licensed pharmacy for an individual patient, based on a physician's prescription. It is not the manufacturer's product, and it is not interchangeable with it.

The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed. The agency has published a page on its concerns with unapproved GLP-1 drugs, covering dosing errors, storage during shipping, and fraudulent products. We think every patient should read it. A few practical points from that page:

• Do not use an injectable GLP-1 medication that arrives warm or without enough cold packs.
• FDA recommends discarding a multi-dose vial 28 days after first use, even if medication remains.
• Use a new, sterile needle and syringe every time.
• Be wary of any seller that says a compounded drug is identical to an approved one.

What large trials measured

The large tirzepatide trials used the manufacturer's product, not a compounded preparation. Their results do not transfer directly to compounded versions.

SURMOUNT-1 (2022). This 72-week trial in The New England Journal of Medicine (Jastreboff et al.) enrolled 2,539 adults with obesity, or overweight plus a weight-related condition, without diabetes. On average, people taking tirzepatide lost substantially more body weight than people taking placebo. The most common side effects were digestive, mostly mild to moderate, and mostly during the period when the dose was being increased. Individual results vary.

SURMOUNT-4 (2024). This trial in JAMA (Aronne et al.) asked what happens after people stop. After 36 weeks on tirzepatide, participants were randomly assigned to continue it or switch to placebo for another 52 weeks. Those who switched to placebo regained a substantial share of the weight they had lost, while those who continued maintained their reduction on average. Individual results vary.

Both trials studied tirzepatide as a long-term medication used with diet and physical activity, not as a short course.

Who may be considered

Your physician makes the decision. In the trials above, adults were generally included if they had a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure or high cholesterol. Your physician will also review your medical history, current medications, and any history of eating disorders.

Common side effects

According to MedlinePlus, the U.S. National Library of Medicine's drug information service, common tirzepatide side effects include:

• Nausea, vomiting, or diarrhea
• Constipation
• Decreased appetite
• Upset stomach

Call your physician right away, or get emergency care, for:

• Stomach pain that will not go away, which may spread to the back, with or without vomiting
• Swelling of the face, throat, or eyes, hives, trouble breathing or swallowing, or a rapid heartbeat
• A lump or swelling in the neck, hoarseness, or trouble swallowing

If you take insulin or other diabetes medication, tirzepatide can raise the risk of low blood sugar. Tirzepatide may also make birth control pills less effective, so ask your physician about backup contraception.

Who tirzepatide is not for

Tirzepatide may not be appropriate if you:

• Have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tirzepatide caused thyroid tumors in rats, and it is not known whether it does in humans.
• Are pregnant, planning a pregnancy, or breastfeeding
• Have had pancreatitis, or have serious stomach problems such as slow stomach emptying
• Have a history of an eating disorder that has not been evaluated
• Are under 18

How ordering works at NUVARA

Start online from home. A U.S.-licensed physician reviews your intake, usually within 24 hours. Your first visit includes a brief live telehealth call to establish care, and refills are usually reviewed online.

If your physician prescribes tirzepatide, the prescription is prepared by one of our US-based partner pharmacies, a state-licensed 503A compounding pharmacy, and shipped to you. NUVARA is not a pharmacy and does not prepare medications. A prescription is required and approval is not guaranteed. Your card is authorized when you order and charged only if the physician approves. If not, the hold is released.

See the Tirzepatide Injectable page. Compounded medication. Not FDA-approved.

Frequently asked questions

What is the FDA status of compounded tirzepatide?

Tirzepatide Injectable at NUVARA is a compounded medication. Not FDA-approved. It is prepared by a licensed partner pharmacy from your physician's prescription.

How is compounded tirzepatide different from the manufacturer's product?

Its active ingredient is tirzepatide, but it is a separate preparation made by a compounding pharmacy, and the FDA has not reviewed it. Trial results for the manufacturer's product do not transfer directly.

What are the most common tirzepatide side effects?

Nausea, vomiting, diarrhea, constipation, decreased appetite, and upset stomach are the most common. They tend to be most noticeable when the dose changes.

What happens if I stop tirzepatide?

In the SURMOUNT-4 trial, people who switched to placebo regained a substantial share of the weight they had lost. Talk with your physician before stopping. Individual results vary.

Who decides my dose?

Your physician. Do not change, pause, or stop your medication without talking to your care team. Consult with your MyNuvara Health physician about any questions.

References

1. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PubMed 30473097 · doi:10.1016/j.molmet.2018.09.009
2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed 35658024 · doi:10.1056/NEJMoa2206038
3. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. PubMed 38078870 · doi:10.1001/jama.2023.24945
4. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. fda.gov
5. MedlinePlus. Tirzepatide injection. U.S. National Library of Medicine. medlineplus.gov

---

Medical disclaimer: This article is for general education only and is not medical advice. It does not replace an evaluation by a licensed clinician. Talk with your MyNuvara Health physician before starting, stopping, or changing any medication. If you think you are having a medical emergency, call 911.